Oncology biotech Dark Blue Therapeutics has been acquired by Amgen for up to $840 million, including upfront and future milestones. Dark Blue's lead candidate DBT 3757, currently in IND-enabling studies, represents a first-in-class therapeutic strategy for acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), with the potential for producing strong, broad and durable responses […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!